Quest PharmaTech Inc.
QPTFF
$0.01
$0.00-11.33%
OTC PK
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.73% | -21.60% | -33.98% | -42.08% | 26.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.04% | -3.63% | -35.91% | -39.65% | -25.26% |
| Operating Income | 14.04% | 3.63% | 35.91% | 39.65% | 25.26% |
| Income Before Tax | 96.51% | 62.25% | 94.54% | 42.87% | 96.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 96.51% | 62.25% | 94.54% | 42.87% | 96.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 96.51% | 62.25% | 94.54% | 42.87% | 96.70% |
| EBIT | 14.04% | 3.63% | 35.91% | 39.65% | 25.26% |
| EBITDA | 70.31% | 36.83% | 44.90% | 39.74% | 25.24% |
| EPS Basic | 96.74% | 62.99% | 95.18% | 43.61% | 96.72% |
| Normalized Basic EPS | 121.05% | 46.15% | 78.79% | 23.40% | 17.39% |
| EPS Diluted | 96.74% | 62.99% | 95.18% | 43.61% | 96.72% |
| Normalized Diluted EPS | 121.05% | 46.15% | 78.79% | 23.40% | 17.39% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.27% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |